Key clinical point: Ado-trastuzumab emtansine is highly efficacious for HER2-amplified salivary gland cancers.
Major finding: The overall response rate was 90%.
Study details: A phase 2 multi-histology basket trial of 10 patients.
Disclosures: Dr. Li reported consulting or advisory roles with Biosceptre International, Guardant Health, Hengrui Therapeutics, Mersana, Roche, and Thermo Fisher Scientific. He reported research funding to his institution from AstraZeneca, BioMed Valley Discoveries, Daiichi Sankyo, GRAIL, Guardant Health, Hengrui Therapeutics, Illumina, and Roche/Genentech. Dr. Noronha has received research funding (to her institution) from Amgen,and Sanofi Aventis.
Li B et al. ASCO 2019: Abstract 6001.